Canada's RetiSpec receives funding for commercialisation of its AI-driven eye test for AD detection

image credit- shutterstock

RetiSpec Inc.,  an innovator in AI-driven eye diagnostics for brain health, announced the successful closing of its $10M USD Series A financing. This funding will enable RetiSpec to accelerate the commercialization of its state-of-the-art technology aimed at early detection of Alzheimer's disease.

The Series A financing was led by iGan Partners and included new strategic investors, Eli Lilly and Company and Topcon Healthcare, Inc., along with existing investors, Gentex Corporation, the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator, Verge HealthTech Fund, University of Minnesota's Discovery Capital, Ontario Brain Institute, Centre for Aging + Brain Health Innovation, and private investors. This financing brings RetiSpec's total fundraising to $17M USD.

RetiSpec's clinically validated test aims to help healthcare providers predict amyloid burden, a core biomarker of Alzheimer's disease. The test is now available for Research Use Only, it is expected to be utilized in routine clinical office visits globally in the near future. RetiSpec's AI solutions applied to non-invasive retinal images, provide real-time assessments at the point of care. The company's goal is to also develop additional AI-driven diagnostics for neurodegenerative diseases and side effects of Alzheimer's therapeutics.